ID: ALA3342213
Max Phase: Preclinical
Molecular Formula: C42H44N2O14
Molecular Weight: 800.81
Molecule Type: Small molecule
Associated Items:
ID: ALA3342213
Max Phase: Preclinical
Molecular Formula: C42H44N2O14
Molecular Weight: 800.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COC(=O)[C@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(OCc5ccc(OCc6c(-c7ccccc7)no[n+]6[O-])cc5)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)C=C(C)C)[C@@H]24
Standard InChI: InChI=1S/C42H44N2O14/c1-21(2)15-30(46)57-34-36-41-20-55-42(36,39(50)52-5)37(48)32(47)35(41)40(4)17-28(45)33(22(3)26(40)16-29(41)56-38(34)49)54-18-23-11-13-25(14-12-23)53-19-27-31(43-58-44(27)51)24-9-7-6-8-10-24/h6-15,26,29,32,34-37,47-48H,16-20H2,1-5H3/t26-,29+,32+,34+,35+,36+,37-,40-,41+,42+/m0/s1
Standard InChI Key: NDGKASWBIXVVPD-ASYKHDRWSA-N
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 800.81 | Molecular Weight (Monoisotopic): 800.2793 | AlogP: 3.04 | #Rotatable Bonds: 10 |
Polar Surface Area: 217.09 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.75 | CX Basic pKa: | CX LogP: 1.65 | CX LogD: 1.65 |
Aromatic Rings: 3 | Heavy Atoms: 58 | QED Weighted: 0.13 | Np Likeness Score: 2.00 |
1. Tang W, Xie J, Xu S, Lv H, Lin M, Yuan S, Bai J, Hou Q, Yu S.. (2014) Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies., 57 (18): [PMID:25179783] [10.1021/jm5007534] |
Source(1):